Table 1.
Incidence of treatment-emergent adverse events in participants receiving a single morning dose of riociguat 2.5 mg, aspirin 500 mg on 2 consecutive mornings, or both treatments concomitantly
| No. (%) of participants | ||||
|---|---|---|---|---|
| Category | Description | Riociguat (n = 15) | Aspirin (n = 17) | Riociguat plus aspirin (n = 16) |
| Cardiac disorders | Ventricular extrasystoles | 1 (6) | ||
| Eye disorders | Conjunctivitis | 1 (6) | ||
| Gastrointestinal disorders | Dyspepsia | 1 (6)a | ||
| General disorders | Injection site swelling | 1 (7) | ||
| General disorders | Vessel puncture site reaction | 1 (7) | ||
| Infections | Rhinitis | 1 (6) | ||
| Investigations | Blood creatine phosphokinase increased | 1 (6) | ||
| Nervous system disorders | Headache | 2 (13)b | ||
| Respiratory disorders | Nasal congestion | 2 (13)a | ||
| Skin disorders | Scar | 1 (6) | ||
a
Considered to be drug related.
b
Moderate in 1 of the 2 incidents, the other was mild; both cases considered to be drug related.